Acutaas Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:39 pm

Quick Insight

Acutaas Chemicals Ltd, a pharmaceutical company, currently trades at a price of 1,414 with a market capitalization of 11,573 Cr. The company's high P/E ratio of 61.2 indicates investors are willing to pay a premium for future earnings growth. Acutaas shows strong returns with a ROE of 16.0% and ROCE of 19.9%, reflecting efficient capital utilization. Operating profit margin stands at 25%, indicating healthy operational efficiency. With reserves of 1,269 Cr and low borrowings of ₹13 Cr, the company appears financially stable. However, the high P/BV ratio of 7.63x suggests the stock may be overvalued. Investors should monitor Acutaas' performance closely to assess sustainability and growth potential in the pharmaceutical industry.

Competitors of Acutaas Chemicals Ltd

All Competitor Stocks of Acutaas Chemicals Ltd

Quarterly Result

Last Updated: August 9, 2025, 11:12 am

Below is a detailed analysis of the quarterly data for Acutaas Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 207.00 Cr.. The value appears to be declining and may need further review. It has decreased from 308.00 Cr. (Mar 2025) to 207.00 Cr., marking a decrease of 101.00 Cr..
• For Expenses, as of Jun 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 224.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 68.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 85.00 Cr. (Mar 2025) to 51.00 Cr., marking a decrease of 34.00 Cr..
• For OPM %, as of Jun 2025, the value is 25.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Mar 2025) to 25.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 10.00 Cr..
• For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 25.00 Cr..
• For Tax %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
• For Net Profit, as of Jun 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 19.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 5.41. The value appears to be declining and may need further review. It has decreased from 7.63 (Mar 2025) to 5.41, marking a decrease of 2.22.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 9, 2025, 11:12 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 9, 2025, 11:12 am

Below is a detailed analysis of the balance sheet data for Acutaas Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 37.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 4.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,269.00 Cr.. The value appears strong and on an upward trend. It has increased from 637.00 Cr. (Mar 2024) to 1,269.00 Cr., marking an increase of 632.00 Cr..
• For Borrowings, as of Mar 2025, the value is 13.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 217.00 Cr. (Mar 2024) to 13.00 Cr., marking a decrease of 204.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 227.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 205.00 Cr. (Mar 2024) to 227.00 Cr., marking an increase of 22.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,549.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,096.00 Cr. (Mar 2024) to 1,549.00 Cr., marking an increase of 453.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 570.00 Cr.. The value appears strong and on an upward trend. It has increased from 427.00 Cr. (Mar 2024) to 570.00 Cr., marking an increase of 143.00 Cr..
• For CWIP, as of Mar 2025, the value is 130.00 Cr.. The value appears strong and on an upward trend. It has increased from 125.00 Cr. (Mar 2024) to 130.00 Cr., marking an increase of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 848.00 Cr.. The value appears strong and on an upward trend. It has increased from 543.00 Cr. (Mar 2024) to 848.00 Cr., marking an increase of 305.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,549.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,096.00 Cr. (Mar 2024) to 1,549.00 Cr., marking an increase of 453.00 Cr..

Notably, the Reserves (1,269.00 Cr.) exceed the Borrowings (13.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Acutaas Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.67 (Mar 24) to 19.81, marking an increase of 8.14.
• For Diluted EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.66 (Mar 24) to 19.81, marking an increase of 8.15.
• For Cash EPS (Rs.), as of Mar 25, the value is 45.69. This value is within the healthy range. It has increased from 17.56 (Mar 24) to 45.69, marking an increase of 28.13.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 319.93. It has increased from 185.13 (Mar 24) to 319.93, marking an increase of 134.80.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 319.93. It has increased from 185.13 (Mar 24) to 319.93, marking an increase of 134.80.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 245.97. It has increased from 194.54 (Mar 24) to 245.97, marking an increase of 51.43.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 60.83. This value is within the healthy range. It has increased from 36.87 (Mar 24) to 60.83, marking an increase of 23.96.
• For PBIT / Share (Rs.), as of Mar 25, the value is 54.33. This value is within the healthy range. It has increased from 32.52 (Mar 24) to 54.33, marking an increase of 21.81.
• For PBT / Share (Rs.), as of Mar 25, the value is 52.81. This value is within the healthy range. It has increased from 22.21 (Mar 24) to 52.81, marking an increase of 30.60.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 39.19. This value is within the healthy range. It has increased from 13.21 (Mar 24) to 39.19, marking an increase of 25.98.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 38.77. This value is within the healthy range. It has increased from 11.60 (Mar 24) to 38.77, marking an increase of 27.17.
• For PBDIT Margin (%), as of Mar 25, the value is 24.73. This value is within the healthy range. It has increased from 18.95 (Mar 24) to 24.73, marking an increase of 5.78.
• For PBIT Margin (%), as of Mar 25, the value is 22.08. This value exceeds the healthy maximum of 20. It has increased from 16.71 (Mar 24) to 22.08, marking an increase of 5.37.
• For PBT Margin (%), as of Mar 25, the value is 21.46. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 21.46, marking an increase of 10.05.
• For Net Profit Margin (%), as of Mar 25, the value is 15.93. This value exceeds the healthy maximum of 10. It has increased from 6.78 (Mar 24) to 15.93, marking an increase of 9.15.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 5.96 (Mar 24) to 15.76, marking an increase of 9.80.
• For Return on Networth / Equity (%), as of Mar 25, the value is 12.11. This value is below the healthy minimum of 15. It has increased from 6.34 (Mar 24) to 12.11, marking an increase of 5.77.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.50. This value is within the healthy range. It has increased from 14.79 (Mar 24) to 16.50, marking an increase of 1.71.
• For Return On Assets (%), as of Mar 25, the value is 10.24. This value is within the healthy range. It has increased from 3.90 (Mar 24) to 10.24, marking an increase of 6.34.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.32 (Mar 24) to 0.01, marking a decrease of 0.31.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.77 (Mar 24) to 0.76, marking a decrease of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 3.91, marking an increase of 2.17.
• For Quick Ratio (X), as of Mar 25, the value is 3.02. This value exceeds the healthy maximum of 2. It has increased from 1.19 (Mar 24) to 3.02, marking an increase of 1.83.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.38. This value is below the healthy minimum of 4. It has increased from 3.19 (Mar 24) to 3.38, marking an increase of 0.19.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 25.55 (Mar 24) to 0.00, marking a decrease of 25.55.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.58 (Mar 24) to 0.00, marking a decrease of 18.58.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 74.45 (Mar 24) to 0.00, marking a decrease of 74.45.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.42 (Mar 24) to 0.00, marking a decrease of 81.42.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 40.04. This value is within the healthy range. It has increased from 22.89 (Mar 24) to 40.04, marking an increase of 17.15.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.80. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 26.80, marking an increase of 12.20.
• For Enterprise Value (Cr.), as of Mar 25, the value is 9,764.07. It has increased from 4,208.12 (Mar 24) to 9,764.07, marking an increase of 5,555.95.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.70. This value exceeds the healthy maximum of 3. It has increased from 5.87 (Mar 24) to 9.70, marking an increase of 3.83.
• For EV / EBITDA (X), as of Mar 25, the value is 39.21. This value exceeds the healthy maximum of 15. It has increased from 30.95 (Mar 24) to 39.21, marking an increase of 8.26.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 9.93, marking an increase of 4.30.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 74.44 (Mar 24) to 0.00, marking a decrease of 74.44.
• For Price / BV (X), as of Mar 25, the value is 7.63. This value exceeds the healthy maximum of 3. It has increased from 5.99 (Mar 24) to 7.63, marking an increase of 1.64.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.93. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 9.93, marking an increase of 4.30.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness